0001209191-23-016392.txt : 20230306 0001209191-23-016392.hdr.sgml : 20230306 20230306170816 ACCESSION NUMBER: 0001209191-23-016392 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230302 FILED AS OF DATE: 20230306 DATE AS OF CHANGE: 20230306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lieu Hsiao D CENTRAL INDEX KEY: 0001468482 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38853 FILM NUMBER: 23709828 MAIL ADDRESS: STREET 1: C/O NGM BIOPHARMACEUTICALS, INC. STREET 2: 333 OYSTER POINT PKWY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER NAME: FORMER CONFORMED NAME: Lieu Hsiao DATE OF NAME CHANGE: 20090716 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NGM BIOPHARMACEUTICALS INC CENTRAL INDEX KEY: 0001426332 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 333 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-243-5555 MAIL ADDRESS: STREET 1: 333 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-03-02 0 0001426332 NGM BIOPHARMACEUTICALS INC NGM 0001468482 Lieu Hsiao D C/O NGM BIOPHARMACEUTICALS, INC. 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 0 1 0 0 SVP, Chief Medical Officer Common Stock 2023-03-02 4 A 0 53000 0.00 A 55605 D Stock Option (Right to Buy) 4.36 2023-03-02 4 A 0 159000 0.00 A 2033-03-01 Common Stock 159000 159000 D Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027. Includes 1,352 shares acquired under the Issuer's Employee Stock Purchase Plan (the "ESPP") on November 15, 2021, 1,252 ESPP shares acquired on May 13, 2022 and 1 ESPP share acquired on November 15, 2022. The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis. /s/ Valerie Pierce, Attorney-in-fact 2023-03-06